Navigation Links
Lannett Reports Strong Fiscal 2015 Third-quarter Financial Results
Date:5/6/2015

PHILADELPHIA, May 6, 2015 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2015 third quarter ended March 31, 2015. 

For the fiscal 2015 third quarter, net sales rose 24% to $99.4 million from $80.0 million in last year's third quarter.  Gross profit increased 35% to $75.6 million, or 76% of net sales, from $56.1 million, or 70% of net sales.  Research and development (R&D) expenses decreased to $9.2 million from $10.6 million for the fiscal 2014 third quarter.  Selling, general and administrative (SG&A) expenses were $12.2 million, compared with $9.6 million.  Operating income grew 51% to $54.3 million from $36.0 million.  Net income attributable to Lannett Company increased 58% to $36.2 million, or $0.97 per diluted share, from $23.0 million, or $0.63 per diluted share, for the prior year third quarter. 

"We have now reported thirteen consecutive quarters in which net sales and adjusted EPS exceeded the comparable prior-year period," said Arthur Bedrosian, chief executive officer of Lannett.  "Our third quarter performance reflects higher sales and gross margin across a number of product categories, partially offset by lower sales of our cardiovascular products, which as expected faced new entrants in the market.  With our strong third quarter and outlook for a solid fourth quarter, we have raised our fiscal 2015 full-year guidance."

For the first nine months of fiscal 2015, net sales rose 59% to $307.6 million from $193.2 million in the comparable prior-year period.  Gross profit was $234.4 million, or 76% of net sales.  This compares with gross profit for the first nine months of fiscal 2014 of $98.5 million, or 51% of net sales, which included a non-recurring pre-tax charge of $20.1 million related to the contract extension with Jerome Stevens Pharmaceuticals, Inc. (JSP).  Excluding the JSP contract renewal charge, gross profit was $118.6 million, or 61% of net sales.  R&D expenses increased to $23.4 million from $21.1 million.  SG&A expenses were $35.6 million, compared with $26.6 million.  Operating income was $175.5 million compared with $50.7 million for the first nine months of the prior year.  Excluding the JSP contract renewal charge, operating income for the prior-year period was $70.8 million.  Net income attributable to Lannett Company was $116.0 million, or $3.13 per diluted share, compared with $33.6 million, or $0.97 per diluted share, for the first nine months of fiscal 2014.  Adjusted net income, which excludes the impact of the JSP contract renewal charge equal to $12.6 million after-tax, was $46.2 million, or $1.34 per diluted share, in the first nine months of fiscal 2014.

Guidance for Fiscal 2015Based on Lannett's current outlook, the company raised its financial guidance for the fiscal 2015 full year as follows:

  • Net sales in the range of $403 million to $408 million, up from previous guidance of $395 million to $405 million;
  • Gross margin as a percentage of net sales of approximately 75% to 76%, up from 74% to 75%;
  • R&D expense in the range of $30 million to $31 million, up from previous guidance of $29 million to $31 million;
  • SG&A expense ranging from $51 million to $52 million, up from $47 million to $49 million;
  • The full year effective tax rate to be in the range of 34% to 35%, unchanged from previous guidance; and
  • Capital expenditures in fiscal 2015 in the range of $30 million to $35 million, which includes $4 million to continue the partial fit-out of two buildings recently acquired by the company, revised from previous guidance of $40 million to $50 million.
  • Conference Call Information and Forward-Looking StatementsLater today, the company will host a conference call at 4:30 p.m. ET to review its results of operations for the fiscal 2015 third quarter ended March 31, 2015.  The conference call will be available to interested parties by dialing 877-261-8992 from the U.S. or Canada, or 847-619-6548 from international locations, passcode 39586832.  The call will be broadcast via the Internet at www.lannett.com.  Listeners are encouraged to visit the website at least 10 minutes prior to the start of the scheduled presentation to register, download and install any necessary audio software.  A playback of the call will be archived and accessible on the same website for at least three months

    Discussion during the conference call may include forward-looking statements regarding such topics as, but not limited to, the company's financial status and performance, regulatory and operational developments, and any comments the company may make about its future plans or prospects in response to questions from participants on the conference call.

    About Lannett Company, Inc.:Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications.  For more information, visit the company's website at www.lannett.com.

    This news release contains certain statements of a forward-looking nature relating to future events or future business performance.  Any such statements, including, but not limited to, achieving the financial metrics stated in the company's guidance for fiscal 2015, whether expressed or implied, are subject to risks and uncertainties which can cause actual results to differ materially from those currently anticipated due to a number of factors which include, but are not limited to, the difficulty in predicting the timing or outcome of FDA or other regulatory approvals or actions, the ability to successfully commercialize products upon approval, Lannett's estimated or anticipated future financial results, future inventory levels, future competition or pricing, future levels of operating expenses, product development efforts or performance, and other risk factors discussed in the company's Form 10-K and other documents filed with the Securities and Exchange Commission from time to time.  These forward-looking statements represent the company's judgment as of the date of this news release.  The company disclaims any intent or obligation to update these forward-looking statements.

    FINANCIAL TABLES FOLLOW LANNETT COMPANY, INC.CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)(In thousands, except share and per share data)Three months ended Nine months ended March 31,March 31,2015201420152014Net sales$
    99,352
    $
    79,997
    $
    307,561
    $
    93,152
    Cost of sales 23,71423,86573,15574,572JSP contract renewal cost---20,100Gross profit75,63856,132234,40698,480Operating expenses:Research and development9,15910,58323,35821,113Selling, general, and administrative12,2049,56035,57926,629Total operating expenses21,36320,14358,93747,742Operating income54,27535,989175,46950,738Other income (loss):Foreign currency gain (loss)(21)1(21)1Gain (loss) on sale of assets(5)-15(55)Gain (loss) on investment securities(103)2005921,765Interest and dividend income95109303204Interest expense(8)(13)(119)(117)Other---(87)Total other income (loss)(42)2977701,711Income before income tax54,23336,286176,23952,449Income tax expense17,97313,28060,20818,838Net income36,26023,006116,03133,611Less: Net income attributable to noncontrolling interest27115545Net income attributable to Lannett Company, Inc.$
    36,233
    $
    22,995
    $
    5,976
    $
    33,566
    Earnings per common share attributable to Lannett Company, Inc.Basic$
    .01
    $
    .66
    $
    3.25
    $
    .01
    Diluted$
    .97
    $
    .63
    $
    3.13
    $
    .97
    Weighted average common shares outstanding:Basic35,880,95435,025,96835,715,06133,082,460Diluted37,210,13836,769,59337,082,13834,586,007 LANNETT COMPANY, INC.CONSOLIDATED BALANCE SHEETS(In thousands, except share and per share data)(Unaudited)March 31, 2015June 30, 2014ASSETSCurrent assets:Cash and cash equivalents

    $
    208,772
    $
    5,587
    Investment securities

    16,61440,693Accounts receivable, net

    79,71561,325Inventories, net42,47444,844Prepaid income taxes4,604-Deferred tax assets11,89411,265Other current assets3,1571,833Total current assets

    367,230265,547Property, plant and equipment, net80,26561,704Intangible assets, net1,166927Deferred tax assets12,77714,234Other assets1,638361TOTAL ASSETS$
    463,076
    $
    342,773
    LIABILITIESCurrent liabilities:Accounts payable$
    ,994
    $
    20,982
    Accrued expenses3,8433,901Accrued payroll and payroll-related expenses

    8,06212,860Rebates payable5,8894,558Income taxes payable

    -4,569Current portion of long-term debt

    134129Total current liabilities

    34,92246,999Long-term debt, less current portion9081,009TOTAL LIABILITIES35,83048,008Commitments and ContingenciesSTOCKHOLDERS' EQUITYCommon stock($0.001 par value, 100,000,000 shares authorized; 36,651,983 and 36,088,272 shares issued; 36,134,991, and 35,571,280 shares outstanding atMarch 31, 2015 and June 30, 2014, respectively)

    3736Additional paid-in capital233,488216,793Retained earnings199,63083,654Accumulated other comprehensive loss(285)(54)Treasury stock(516,992 shares at March 31, 2015 and June 30, 2014)(5,959)(5,959)Total Lannett Company, Inc. stockholders' equity

    426,911294,470Noncontrolling interest335295Total stockholders' equity

    427,246294,765TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $
    463,076
    $
    342,773
     

    Contact:

    Robert JaffeRobert Jaffe Co., LLC(424) 288-4098Logo - http://photos.prnewswire.com/prnh/20150417/199461LOGO

     


    '/>"/>
    SOURCE Lannett Company, Inc.
    Copyright©2015 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Lannett Expands Revolving Credit Facility To $120 Million
    2. Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Lannett Company, Inc.
    3. Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc.
    4. NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance
    5. Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results
    6. Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria
    7. Isis Reports Financial Results and Highlights for First Quarter 2015
    8. ANI Pharmaceuticals Reports First Quarter 2015 Financial Results
    9. Luminex Corporation Reports First Quarter 2015 Results
    10. Xencor Reports First Quarter 2015 Financial and Operating Results
    11. AcelRx Pharmaceuticals Provides Zalviso Regulatory Update and Reports First Quarter 2015 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/25/2017)... 2017   Montrium , an industry leader ... the IQPC Trial Master Files & Inspection Readiness ... EastHORN Clinical Services has selected eTMF Connect ... management. EastHORN, a leading European contract research organization ... transparency to enable greater collaboration with sponsors, improve ...
    (Date:9/19/2017)... medical device company developing a non-invasive, robotically assisted, platform therapy that uses pulsed sound energy ... ... Jim Bertolina, PhD ... Tom Tefft ... executive Josh Stopek , PhD, who has led R&D and business development teams at ...
    (Date:9/12/2017)... and NEW YORK , Sept. 12, 2017   ... for global supply chains, has published the first annual edition of its ... of more than 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings ... 2016. ... CSR Risk & Performance Index ...
    Breaking Medicine Technology:
    (Date:10/12/2017)... , ... October 12, 2017 , ... IsoComforter, Inc. ( ... announced today the introduction of an innovative new design of the shoulder pad. ... you get maximum comfort while controlling your pain while using cold therapy. By utilizing ...
    (Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
    (Date:10/12/2017)... ... , ... Leading pediatric oncology experts at Children’s National Health System ... of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of the ...
    (Date:10/12/2017)... ... October 12, 2017 , ... Health ... interactive health literacy software tool, and the Cancer Patient Education Network (CPEN), an ... education, today announce a new strategic alliance. , As CPEN’s strategic partner, ...
    (Date:10/12/2017)... ... October 12, 2017 , ... ... University of California Berkeley, and other leading institutions in announcing the launch of ... institutions to change the way animals are raised for food. , Founding members ...
    Breaking Medicine News(10 mins):